|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report the case of a 65-year-old man with castration-resistant metastatic prostate cancer who underwent Ga-PSMA ligand PET/CT for restaging of disease.
|
27997422 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of 177Lu-PSMA-617 and External Radiotherapy for the Treatment of Cerebral Metastases in Patients With Castration-Resistant Metastatic Prostate Cancer.
|
28719450 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A biopsy was performed, and histological examination revealed multiple myeloma with PSMA expression in the neovessels but no metastatic prostate cancer cells.
|
28737577 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that increase in PSMA in prostate tumors contributes to progression by altering normal signal transduction pathways to drive PCa progression and that enhanced signaling through the IGF-1R/β<sub>1</sub> integrin axis may occur in other tumors.
|
28292957 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA) PET has been recently introduced for the diagnosis of patients with metastatic prostate cancer (PCa).
|
29107272 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tc-labeled PSMA inhibitor MIP-1404 is a promising SPECT tracer for detection of locally recurrent or metastatic prostate cancer.
|
27775936 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>F-DCFPyL is a small-molecule inhibitor of the prostate-specific membrane antigen that has shown promise for evaluation of primary and metastatic prostate cancer using PET.
|
27932557 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Utility of 68Ga-PSMA PET/CT in Poorly Differentiated Metastatic Prostate Cancer.
|
28319496 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prostate-specific membrane antigen (PSMA), which is highly expressed in both localized and metastatic prostate cancer (PCa), is an ideal target for imaging and therapy of PCa.
|
28964633 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>68</sup>Ga-PSMA-11 PET as a Gatekeeper for the Treatment of Metastatic Prostate Cancer with <sup>223</sup>Ra: Proof of Concept.
|
27660148 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ga-PSMA ligand PET/CT is a highly sensitive and specific imaging method for the detection of primary and metastatic prostate cancer and has refined diagnostic approaches.
|
28368893 |
2017 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data demonstrate that the PSMA-specific theranostic nanoplex can deliver gene therapy and prodrug enzyme therapy concurrently for precision medicine in metastatic prostate cancer.
|
26706476 |
2016 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The interference of the proinflammatory cytokine, IL-6, with bFGF signaling and PSMA, should be of high clinical relevance in the treatment of metastatic prostate cancer.
|
23250823 |
2013 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
|
18942640 |
2009 |
|
Metastatic Prostate Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results thus provide a strong rationale for undertaking phase I clinical studies to assess PSMA-targeted T cells in patients with metastatic prostate cancer.
|
16204083 |
2005 |
|
Metastatic Prostate Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results of the first detailed quantitative analysis of PSMA mRNA expression in patient's tissues demonstrate that PSMA and the 3 PSMA splice variants are expressed in normal, benign, cancerous and metastatic prostate cancer.
|
12949815 |
2003 |
|
Metastatic Prostate Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The PCR assay using PSM primers-1 showed DNA bands for 4 of 7 cases of metastatic prostate cancer and amplified the untreated genomic DNA, while that using PSM primers-2 showed 6 bands without the amplification of the genomic DNA.
|
10189895 |
1999 |